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Background: Semicarbazide-sensitive amine oxidase (SSAO; EC; 1.4.3.6.) has widespread
tissue distribution, and the physiological role of SSAO is quite well known through its
involvement in several pathological states.
Aims: The present study examined modulators of SSAO which might be present in the rat
heart cytosol and looked for changes in SSAO modulatory activity.
Methods: An endogenous inhibitor of SSAO was separated by gel ﬁltration from 105,000 g
supernate of T4-treated rat heart cytosol. SSAO inhibition fraction was referred to as
‘‘endogenous SSAO inhibitor’’.
Results: The inhibition by this inhibitor was concentration-dependent. Inhibition of SSAO
was not enhanced by varying the time of preincubation of the enzyme, indicating reversible
inhibition of SSAO. The molecular weight of this inhibitor was estimated to be 1000–1100 by
gel ﬁltration. The isoelectric point (pI) value was determined to be 4.8 isoelectric focusing.
This inhibitor was found to be heat-stable and resistant to protease treatment. SSAO
inhibition activity was much lower in the cytosol of thyroidectomized, non-T4-treated rats
than T4-treated rats, suggesting that this inhibitor was induced by thyroid hormone T4.
SSAO activity in rat heart might be regulated by the level of this inhibitor.
Conclusion: These results suggest the presence of SSAO inhibitor in T4-treated rat cytosol
and that the level of this inhibitor is regulated by thyroid hormone.
# 2016 Published by Elsevier B.V. on behalf of Cardiological Society of India.
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Semicarbazide-sensitive amine oxidase (SSAO)1,2 differs from
monoamine oxidase (MAO; EC 1.4.3.4) and deaminates various
monoamines.3 Although they are all classiﬁed as the amine* Corresponding author.
E-mail address: t-obata@osaka-aoyama.ac.jp (T. Obata).
Abbreviations: SSAO, semicarbazide-sensitive amine oxidase; MA, 
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0019-4832/# 2016 Published by Elsevier B.V. on behalf of Cardiologicaoxidase (copper-containing) (EC 1.4.3.6), they comprise a large
group of enzymes with different substrate speciﬁcities and
tissue distributions. SSAO is the name used for the benzyla-
mine oxidizing activity that remains after pretreatment with
acetylenic MAO inhibitor, clorgyline or deprenyl.4 SSAO
activity is suspected to cause damage, such as diabetes inOmonoamine oxidase; ESI, endogenous SSAO inhibitor.
l Society of India.
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metabolites with cytotoxic effects or reactive oxygen species
and (b) as an adhesion molecule, in leukocyte trafﬁcking, in
regulating glucose uptake, and in adipocyte homeostasis.6 The
role of SSAO is quite well known through its involvement in
several pathological states, where its increased serum activity
has been found: diabetes mellitus, congestive heart failure,
multiple types of cerebral infarction, uremia, and liver
cirrhosis. It plays a detrimental role in vascular diseases,
particularly atherosclerosis, and its role in the pathophysiolo-
gy of these conditions has been extensively investigated, from
which its role may be deduced.
One of the important actions of thyroid hormone is
thought to be the regulation of protein synthesis and enzyme
activities.7 On the contrary, MAO activity in various organs of
was shown to be diminished by thyroid hormone8 or by a
pituitary factor,9 which is known to increase the secretion of
thyroid hormones. In the latter case, it is not clear, whether
thyroid hormones affect the protein synthesis of MAO or act by
another mechanism (e.g. induction of speciﬁc modulator).
There are many reports on the possible existence of the
multiple modulators of MAO being present in the cytosol
fractions of various organs of animals.10–12 These studies
imply that endogenous MAO modulators might be important
in the physiological regulation of MAO activity. None of these
investigators, however, provide any information about exis-
tence of endogenous SSAO inhibitor (ESI).
In the present study, we found an ESI in rat heart cytosol,
and this inhibitor could be induced by thyroid hormone T4.
2. Methods
2.1. Chemicals
Semicarbazide, clorgyline hydrochloride, deprenyl hydrochlo-
ride, benzylamine hydrochloride, T4 sodium salt, subtilisin
(protease Type III), and protease E (protease Type XIV) were
purchased from the Sigma Chemical Co. (St. Louis, MO, USA).
The radioactive substrate [7-14C]-benzylamine hydrochloride
(1.85–2.29 Gbq/mmol) was obtained from Amersham Interna-
tional (Amersham, England). Servalyte (pH 2–11) was pur-
chased from Serva Fine Biochemical Co. (St. Louis, MO, USA).
2.2. Isolation of SSAO inhibitor
Thyroidectomized rats (Male Wistar), weighing 100–150 g,
were used for experiments. In the case of T4 administered
rats, T4 (dissolved in saline) was injected subcutaneously to
the rats after 10 days from operation at a dose of 200 mg/kg per
day for 2 weeks. The rats were killed by decapitation and heart
quickly removed and homogenized in 10 vol. of 10 mM
phosphate buffer, pH 7.4 containing 0.25 M sucrose. The
homogenates was centrifuged at 105,000 g for 60 min, and
the supernate (cytosol fraction) was applied on a Sephadex
G-25 column (1.0  60 cm), previously equilibrated with 20 mM
phosphate buffer (pH 7.4). The column was eluted with the
same buffer at a rate of 10 ml/hr and the fractions were
collected in 2.5 ml each. An aliquot of each fraction was
assayed for SSAO inhibition activity, and active fractions werecombined and used for further characterization. This fraction
is referred to as ‘‘ESI’’.
2.3. Assay of SSAO activity
Rat heart homogenate fraction was used as a source of SSAO
activity. The 10% homogenate of this was prepared in 0.25 M
sucrose with 10 mM phosphate buffer, pH 7.4. SSAO activity
was assayed radiochemically.13 Assay mixture contained 20 ml
of homogenate fraction (100 mg/ml protein), [14C]-benzylamine
(1 mM), in 20 mM phosphate buffer, pH 7.4 (20 ml) in the
presence of ESI (0–140 ml). After a 10-min preincubation at
37 8C, the mixture was diluted with the solution of respective
unlabeled amines, and the reaction was stopped by adding 2 N
HCl (200 ml). The products of the reaction were extracted with
2 ml of benzene-ethyl acetate (1:1, v/v) saturated with water.
Triton X-100 toluene scintillation liquid (10 ml) was added to
1.0 ml samples of the extract, and the radioactivity was
measured in Beckmann LS-9000 scintillation spectrometer. In
inhibition studies, enzyme preparation was preincubated with
various concentration of semicarbazude, clorgyline and
deprenyl for 30 min at 37 8C before adding [14C]-benzylamine
for assay of remaining SSAO activity. The reaction products
were extracted with ethyl acetate-benzene (1:l, v/v) and the
radioactivity was counted. Protein concentrations of the
preparations were measured by the method of Lowry et al.
with bovine serum albumin as the standard.14
2.4. Isoelectric focusing (IEF)
Gel IEF was performed by the method of Fawcett.15 The ﬁnal
composition of the gel was 5% acrylamide, 0.2% methylene
bisacrylamide, 0.75% Triton X-100, 2% servalyte (pH 2–11),
0.0002% riboﬁavin, 0.01% ammonium persulfate, 0.05% TEMED
(N,N,N0,N0-tetramethylenediamine). The gel was mounted on a
vertical apparatus containing 0.01 M H3PO4 in the upper tank
(anode)and0.02 M NaOH inthelower tank(cathode).Thecurrent
was at 100 V for the ﬁrst 1 h, 200 V for the next 2 h and then 300 V
for 2 h. After electrophoresis, the gel was cut into 4 mm thick
slices, and each sliced gel was placed in a test tube and incubated
for 1 h at room temperature by adding 1 ml of distilled water and
bubbled with N2 gas. After the measurement of slice pH, a
minimum amount of 0.5 M H3PO4was added to adjust the pH to
7.4. An aliquot of each slice suspension was then assayed for
SSAO inhibition activity with benzylamine as a substrate.
2.5. Statistical analysis
All values are presented as means  S.E.M. The signiﬁcance of
difference was determined by using ANOVA with Fisher's post
hoc test. A p value of less than 0.05 was regarded as being
statistically signiﬁcant.
3. Results
3.1. Inhibition of SSAO activity in rat
As shown in Fig. 1, in vitro inhibition of SSAO activity in rat
heart homogenate by clorgyline, deprenyl, and semicarbazide
Fig. 1 – Inhibition of benzylamine deamination in rat heart
by clorgyline, deprenyl and semicarbazide. The enzyme
preparation was preincubated with clorgyline (open circle),
deprenyl (triangle), and semicarbazide (square) at 37 8C for
30 min. Enzyme activity was assayed radiochemically by
addition of 1 mM benzylamine as substrate at 37 8C for
10 min. Each point represents the mean percentages (WS.E.)
on the control SSAO activity in triplicate experiments.
Fig. 2 – Sephadex G-25 chromatography of cytosolic fraction
from T4-treated rat heart. Cytosolic fraction (10 mg protein)
was applied to a Sephadex G-25 column (1.0 T 60 cm). (A)
ESI-control (closed circle) or ESI-T4 (open circle) was
obtained from thyroidectomized rat or thyroidectomized,
T4-treated rat, respectively, as described in the text. The
activity of SSAO in homogenate was assayed with 1 mM
benzylamine as a substrate. Arrows indicate the position of
marker compounds. The molecular for markers used were
as follows: (a) cyanocobalamine (MW, 1355); (b) FAD (MW,
786); (c) DNP-alanine (MW, 255). Vo; dextran (MW,
2,000,000). The broken line shows the absorbance at
280 nm. (B) Estimation of molecular weight of ESI-T4 by gel
filtration with Sephadex G-25. The arrows show the
mobility of the peak of inhibition activity.
Fig. 3 – Concentration-dependent effect of ESI (open circle)
without preincubation (closed circle). In the presence of
150 ml of ESI T4, SSAO activity in rat heart homogenate was
determined 1 mM benzylamine as substrate at 37 8C for
10 min. The control activities for 1 mM benzylamine were
0.23 W 0.02 nmol/min/mg protein. Values are means W S.E.
M. for six animals. *p < 0.05 versus control (buffer) (ANOVA
and Fisher test). §p < 0.001 versus significant difference
between the data connected by each bracket (ANOVA and
Fisher's test).
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enzyme was preincubated at 37 8C for 30 min with various
concentrations of clorgyline and deprenyl, the deamination of
1 mM benzylamine was not inhibited at high concentration of
these inhibitors, while it was highly sensitive for semicarbazide.
The complete inhibition at 104 M semicarbazyde was obtained.
3.2. Separation of ESI
The gel-ﬁltration of T4-treated rat heart cytosol with Sephacryl
S-200 column showed that the fractions to inhibit SSAO
activity were eluted in a low molecular weight area (<2000)
(data not shown). Therefore, we used Sephadex G-25 column
to separate the inhibitor and determine the molecular size
(Fig. 2A). The fractions 15–17 were found to inhibit SSAO
activity with 1 mM benzylamine being used as a substrate. The
molecular weight of the inhibitor was estimated to be 1000–
1100 (Fig. 2B). Some endogenous SSAO activity was observed in
fractions 6–9. When thyroidectomized, non-T4-treated rats
were used (ESI-control), the inhibition activities for 1 mM
benzylamine were very low. T4-treatment remarkably en-
hanced SSAO inhibition activities for substrate. These results
suggest that the inhibitor could be induced by T4 treatment.
The effect of concentration of the inhibitor on SSAO activity
was examined using 1 mM benzylamine as a substrate. The
inhibition curves of SSAO activity by ESI were concentration
dependent, and IC50 values for 1 mM benzylamine oxidation
were 105 ml (Fig. 3).
3.3. Isoelectric point (pI) of ESI
The pI value of ESI was determined by gel isoelectric-focusing
(Fig. 4). SSAO inhibition activity was found as a single peak at a
position 2.8 cm from the top of the gel. The pH measurement
after IEF revealed that ESI has a pI value of about 4.8.
3.4. Some properties of ESI
Study of the time-course inhibition of SSAO by ESI inhibited
that extent of the inhibition did not change even for
Fig. 4 – Effect of preincubation time with ESI on SSAO in the
rat heart. Rat heart homogenates were preincubated with
ESI at 37 8C for the incubation times, and then remaining
SSAO activity was assayed, as described in the text. Values
were expressed as percent inhibiting SSAO activity in
preparations preincubated with distilled water for the
same periods. Each point represents the mean percentage
activity (WS.E.) assayed in triplicate experiments with
respect to homogenates preincubated for the same length
of the time but with distilled water instead of ESI.
Fig. 5 – Estimation of pI value of ESI-T4 in rat heart cytosol
by gel isoelectric focusing. ESI-T4 fraction was collected
and was solubilized with 0.75% Triton X-100. Isoelectric
focusing was performed as described in Materials and
Methods. After IEF-gel electrophoresis, the gel was cut into
4-mm slices, and the pH (open circle) of each gel slice was
determined. After adjusting pH to 7.4, the SSAO activity for
1 mM benzylamine was determined in the presence of each
gel slice (closed circle) without preincubation. The control
activity for benzylamine was 0.23 W 0.02 nmol/min/mg
protein. Each point represents the mean percentages (WS.
E.) on the control SSAO activity in triplicate experiments.
Fig. 6 – Some properties of the ESI treatment. ESI-T4 was
tested in various ways, such as nontreatment (N), heat
treatment (H; 100 8C for 10 min), trypsin (T; 37 8C for
30 min), subtilisin (S; 37 8C for 12 h), and pronase (P; 37 8C
for 12 h). Control (C) values for SSAO activity were
0.23 W 0.02 nmol/min/mg protein. Values of percentage
SSAO activity are means W S.E.M. for six animals, *p < 0.05
versus control (ANOVA and Fisher test).
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treated at 100 8C for 10 min, the inhibition activity was not
changed. Also, treatment of ESI with subtilisin or pronase at
37 8C for 12 h did not affect the inhibition activity of ESI. These
results suggest that ESI is a non-peptide inhibitor (Fig. 6).
4. Discussion
It is well established that one of the actions of thyroid
hormones is thought to be the regulation of protein synthesis
and enzyme activities.7,16,17 Thyroid hormones were also
found to inﬂuence of MAO activity in the rat heart.18 Ichikawa
et al.19 reported that endogenous MAO modulators isolated
from the rat heart cytosol. SSAO differs from MAO and
deaminates various monoamines.20 The cardiac MAO activity
was increased in hyperthyroid rats or by administration ofthyromimetic compounds.21 Thyroid hormone is shown to be
protective against cardiac injury. The cardiovascular system is
an important target for thyroid hormones. However, there is
no information about SSAO activity. It is possible that thyroid
hormone regulates the SSAO activity in rat heart. It is not
known, whether a decrease in SSAO activity in hyperthyroid
state is a direct effect of thyroid hormone or is mediated
through speciﬁc mechanism. In the present study, we found
the presence of thyroid hormone inducible endogenous SSAO
modulator in rat cardiac cytosol fraction, which could inhibit
SSAO activity. To our knowledge, this is ﬁrst report on SSAO
modulator in rat heart.
Although its physiological role is not yet clear, SSAO in
certain rat cardiovascular tissues deaminate various mono-
amine such as benzylamine, b-phenylethylamine, kynura-
mine and dopamine.22 This enzyme in other rat tissues
deaminates other monoamines. Benzylamine is the best
substrate so far examined for this enzyme. It is well known
that low concentration of benzylamine (1 mM) was deaminated
solely by SSAO.23 Metabolism of benzylamine by SSAO has a
Km of around 5 mM, which is much lower than for benzylamine
metabolism by MAO activities.24 Therefore, the complete
inhibition at 104 M semicarbazide was obtained (Fig. 1). When
corresponding experiments were performed with 100 mM
benzylamine, the opposite results were obtained (not illus-
trated). Although SSAO is present in plasma, SSAO activity in
blood was very low (data not shown).
There have been many reports on the effects of thyromi-
metic compounds on MAO activity, whereas the others report
that the cardiac MAO activity was increased in hyperthyroid
rats or by administration of thyromimetic compound.25 We
found an endogenous SSAO modulator of a low molecular
weight (1000–1100) in heart cytosol of T4-treated rats (Fig. 2).
The inhibitory effects of this inhibitor were non-linear
concentration-dependent (Fig. 3). This molecular weight is
much smaller than that reported for rat MAO modulator19
(8500–35,000). When thyroidectomized, nontreated rats were
used, inhibition activities for benzylamine were very low.
However, T4-treatment remarkably enhanced SSAO inhibition
activities for benzylamine (Fig. 3). The fact that the inhibitory
activity in the hyperthyroid state suggests the possibility that
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of this inhibitory modulator. We previously reported that an
endogenous MAO inhibitor of a low molecular weight (600–700)
in liver cytosol of T4-treated rats.26 This molecular weight is
similar to ESI (1000–1100) in cardiac cytosol of T4-treated rats.
It can be concluded that the rat heart contains low molecular
weight materials which act like SSAO inhibitor drugs. The
nature of the inhibition of SSAO by ESI was studied. Time-
course experiments indicated that this enzyme was inhibited
equally effectively in the absence of preincubation as after
90 min of preincubation (Fig. 5). Moreover, dilution experi-
ments showed that the dilution of the reaction mixture
restored the activity to the level at ﬁnal concentration of the
inhibitor (data not shown), suggesting that the inhibition is
reversible. These may indicate that ESI was a reversible
inhibitor of SSAO.
The present study showed that this compound is heat-
stable and resist to protease and subtilisin treatment (Fig. 6).
Our ﬁndings suggested that thyroid hormone-inducible SSAO
inhibitor may have an important role in SSAO activity. We also
discussed the physiological role of involvement in the thyroid
hormone-mediated regulation of vascular function.
5. Conclusion
In the present study, we found a new SSAO inhibitory
modulator in T4-treated rat cardiac cytosol, and that the level
of this modulator is regulated by thyroid hormone. Although
the physiological role of this inhibitor still remains unclear, we
consider that this modulator may play some role in regulating
the SSAO activity in rat heart. While the role of these
modulators is no doubt important, their mechanisms remain
to be elucidated. Further study will be necessary to clarify this
point.
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